Introduction
============

Intravitreal injection of triamcinolone acetonide (TA) is an efficient method for delivering the drug to the vitreous to avoid systemic side effects, and has been widely used for treating ophthalmic diseases such as diabetic retinopathy \[[@r1]\], retinal vein occlusion \[[@r2]\], and uveitis \[[@r3]\]. In addition, it has also been combined with photodynamic therapy recently \[[@r4]\].

Intravitreal injection of 4 mg/0.1 ml TA is the most popular choice for ophthalmologists \[[@r5],[@r6]\]. Because diseases such as macular edema frequently recur, patients should receive repeated intravitreal injections of TA after a specific period. Jonas suggested that with a higher dose, considerably longer intraocular availability of TA might be achieved \[[@r7]\]. In this report, we speculated that increasing the dose of intravitreal TA could prolong the effects of the drug on the retina and relieve patients from suffering repeated injections. Although TA has already been applied on a large scale for years, little is known about the pharmacokinetics of the drug \[[@r8]-[@r17]\], especially since there is no consensus on whether TA has retinal toxicity \[[@r18]-[@r26]\]. Thus, the purpose of this study is to compare the pharmacokinetics and retinal toxicity of intravitreal commercial TA at various doses (4 mg and 8 mg) in rabbit eyes. These findings may provide important information for the clinical application of TA.

Methods
=======

Drug preparations, animals, and animal experiments
--------------------------------------------------

The 4 mg/0.1 ml dose of TA was obtained directly from commercially available TA (40 mg/ml, Kunming Jida Pharmaceuticals, Kunming, China). The 8 mg/0.1 ml concentration of TA was obtained with the following method. Commercial TA of 0.2 ml was spun down in centrifuge for 5 min at 1698 ×g; thereafter, the half supernatant was removed, and the remnant was mixed. Methanol (high-performance liquid chromatography \[HPLC\] grade) was purchased from Merk (Hamburg, Germany).

Adult female and male New Zealand white rabbits (2.0--2.5 kg) were obtained from the Laboratory Animal Center of Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China), and all experimental procedures adhered to the guidelines of the Chinese Animal Administration and the Association for Research in Vision and Ophthalmology Statement for the use of animals in ophthalmic and vision research.

All rabbits were anesthetized with an intramuscular injection of ketamine hydrochloride (30 mg/kg) and chlorpromazine hydrochloride (15 mg/kg). Topical anesthesia was achieved with tetracaine hydrochloride. Tropicamide was applied to dilate the pupils. A baseline eye examination including slit-lamp biomicroscopy, funduscopy with direct ophthalmoscope, and intraocular pressure (IOP) measurement were performed. Before intravitreal injection, paracentesis with removal of 0.1 ml of aqueous humor was performed to avoid an increase in IOP. Intravitreal injection of 0.1 ml solution was performed after a sterile eyelid speculum was placed, using a 30-gauge needle in the superior temporal quadrant about 2.5 mm posterior to the limbus.

Pharmacokinetics
----------------

Forty-two rabbits were randomly divided into two groups of 21 animals each. Group 1 was intravitreally injected with 4 mg/0.1 ml TA, and six eyeballs were obtained by euthanizing three rabbits with an intravenous injection of 100 mg/kg sodium pentobarbital at 0, 7, 14, 30, 45, 70, and 130 days after TA injection. Group 2 received intravitreal injection of 8 mg/0.1 ml TA, and six eyeballs were obtained at 0, 10, 20, 35, 60, 90, and 150 days after TA injection.

Each eyeball was enucleated and immediately frozen in a −60 °C environment. The vitreous was isolated using the previously described technique by separating frozen vitreous from the sclera, retina, lens, cornea, and so on \[[@r13]\]. Each eyeball was enucleated and immediately frozen in a -60 °C environment, and the frozen vitreous was harvested carefully by separating sclera, retina, lens, cornea, and so on \[[@r13]\]. Vitreous samples were subjected to ultrasonic processor for 20 s at 0 °C (mixture with water and ice). The mixed vitreous of 0.1 ml was pretreated with the addition of 4.9 ml methanol. The mixture was blended and centrifuged at 1698 ×g for 30 min, and 20 μl of each supernatant was directly injected into reversed-phase HPLC (Shimadzu LC-10AD liquid chromatography equipped with SPD-10A UV detector, class-10A workstation system, Rheodyne injector, and 20-μl sample loop) to analyze the data. The Diamonsil C-18 chromatographic column (5 µm particle size, 250 mm × 4.6 mm, Dikma Technologies, Beijing, China) was used for separation, and detection was set at 254 nm. The mobile phase was composed of methanol:water (70:30) at a flow rate of 1.0 ml/min. The column oven was set at 40 °C. The TA retention time was 6.8 min, and the detection limit was 0.005 mg/ml. The standard curve was linear from 0.005 to 0.100 mg/ml (correlative \>0.9998), using seven different amounts of TA standard. The concentrations of 0.01 mg/ml, 0.06 mg/ml, and 0.10 mg/ml TA in vitreous were measured for the recovery and intra- and inter-day reproducibility.

Retinal toxicity
----------------

Twenty rabbits were divided into two experimental groups: Ten right eyes in group A were injected with 4 mg/0.1 ml TA, and ten right eyes in group B were injected with 8 mg/0.1 ml TA. All left eyes were injected with 0.1 ml physiologic salt solution (PSS) as the control group.

IOP measurement was performed with a Schiötz ophthalmotonometer (Suzhou, China) before intravitreal injection and at 1, 4, 8, and 12 weeks following injection. All animals were kept in a quiet environment for about 30 min and then received topical anesthesia. After the eyelid was separated, the central part of the cornea was gently touched with the Schiötz ophthalmotonometer.

Electroretinography (ERG) was performed before intravitreal injection and at 1 and 3 months after injection using the method previously reported \[[@r27]\]. Briefly, the rabbits received dark adaption for at least 30 min before anesthesia and pupillary dilatation with the described methods. A silver electrode was placed on the cornea and served as a positive electrode. The reference electrode was placed subcutaneously between the base of the ear and the lateral canthus. The ground electrode was placed subcutaneously at the forehead area. The ERG included 30 Hz flicker, scotopic 0.5 Hz every 5 min during the 30 min of dark adaptation, with a flash intensity of 3.0 cd•s/m^2^.

The animals were euthanized, and both eyes were enucleated at 3 months after the last ERG. Enucleated eyes were fixed in 10% formalin for light microscopic examination, or 2.5% glutaraldehyde for transmission electron microscopy. Light microscopic sections were stained with hematoxylin-eosin, and transmission electron microscopic sections were stained with lead and uranyl acetate.

Statistical analysis
--------------------

The elimination half-life (t~1/2~), initiate theoretical concentration (Co), and area under the concentration time curve (AUC) were calculated with 3p97 pharmacokinetics software (Practical Pharmacokinetics Software, Beijing, China). Using SPSS 13.0 (SPSS Inc., Chicago, IL), the IOP and ERG b-wave amplitude data were compared by using repeated measures ANOVA. p\<0.05 was considered significant.

Results
=======

Pharmacokinetics
----------------

Chromatograms of TA in samples are shown in [Figure 1](#f1){ref-type="fig"}. TA was separated clearly and was not interfered by the other substances. The recovery and intra- and inter-day reproducibility results are shown in [Table 1](#t1){ref-type="table"}. The mean recovery from the vitreous was 98.36%. These data suggested that TA could be efficiently extracted from the vitreous via this method, and analyzing the TA concentration of intravitreal injection was reliable.

![Triamcinolone acetonide (TA) concentration time profiles in the vitreous of rabbits following intravitreal injection of TA. The concentrations of intravitreal 4 mg (**A**) and 8 mg (**B**) TA decreased gradually with time. Values represent mean±SD (n=6). Typical high-performance liquid chromatography chromatograms of triamcinolone acetonide. **A**: Blank rabbit vitreous control. **B**: Blank rabbit vitreous+TA. **C**: The sample of rabbit vitreous after intravitreal injection of TA.](mv-v20-629-f1){#f1}

###### Results of recovery and precision of TA

  Concentration (mg/ml)   Recovery χ**±** RSD%   Intraday χ**±** RSD%   Interday χ**±** RSD%
  ----------------------- ---------------------- ---------------------- ----------------------
  0.01                    0.0097±0.0003          0.0090±0.0002          0.0094±0.0003
  0.06                    0.0591±0.0017          0.0605±0.0030          0.0582±0.0021
  0.1                     0.0997±0.0019          0.0997±0.0012          0.0962±0.0035

χ: mean values, n=5; RSD: relative standard deviation.

[Figure 2](#f2){ref-type="fig"} shows the time course of the TA concentration in the vitreous of the rabbits following intravitreal injection of 4 mg and 8 mg TA. The concentrations of both doses decreased gradually with time, and the peak concentration of intravitreal TA was the initial concentration. A concentration of 0.0524 mg/ml was maintained in the vitreous at 130 days after the injection of 4 mg TA, and 0.2606 mg/ml was detected at 150 days following the intravitreal injection of 8 mg TA. The calculated half-lives of intravitreal TA were 24 days for the 4 mg dose and 34 days for the 8 mg dose. The initiate theoretical concentration of intravitreal 4 mg and 8 mg TA were 2.745 mg/ml and 5.498 mg/ml, and the AUC were 95.560 (mg/ml)/d and 247.789 (mg/ml)/d, respectively. These data show that intravitreal injection of 8 mg TA achieved a longer half-life and higher concentration and bioavailability compared with the intravitreal injection of 4 mg TA.

![Triamcinolone acetonide concentration time profiles in the vitreous of rabbits following intravitreal injection of triamcinolone acetonide. The concentrations of intravitreal 4 mg (**A**) and 8 mg (**B**) triamcinolone acetonide (TA) decreased gradually with time. Values represent mean±SD (n = 6).](mv-v20-629-f2){#f2}

Retinal toxicity
----------------

The vitreous was transparent with the intravitreal injection of PSS, and TA was visible as a white mass in the vitreous after the injection ([Figure 3](#f3){ref-type="fig"}). The size of the mass became gradually smaller. No endophthalmitis, keratic damage, cataract, vitreous hemorrhage, or retinal detachment was discovered during the study period. The IOP and b-wave amplitudes for each group at different time points are shown in [Figure 4](#f4){ref-type="fig"} and [Figure 5](#f5){ref-type="fig"}. There was no significant difference in IOP between any groups (*F =* 0.316, p = 0.732\>0.05) or between any time points (*F =* 0.835, p =0.507\>0.05), and there were no significant differences between any groups (*F =* 1.868, p = 0.167\>0.05) or between any time points (*F =* 0.079, p = 0.925\>0.05) in the ERG b-wave amplitudes. The histopathologic examination of both groups showed no structural abnormalities under light microscopy at 3 months, and normal layers of retina were revealed in both groups ([Figure 6](#f6){ref-type="fig"}). Transmission electron microscopy confirmed these findings and demonstrated a complete normal retina in each group. The outer nuclear layer and the inner nuclear layer are normal in [Figure 7A,B](#f7){ref-type="fig"}. The inner and outer segments of the photoreceptors are also normal at 3 months in [Figure 7C,D](#f7){ref-type="fig"}. These results suggest that intravitreal injection of 4 mg and 8 mg TA is safe for the rabbit retina.

![Digital color fundus photography of the rabbit after intravitreal injection of triamcinolone acetonide. Triamcinolone acetonide (TA) injected into the vitreous aggregated to form a white drug depot.](mv-v20-629-f3){#f3}

![Intraocular pressure for each group at different time. Intraocular pressures was obtained with the Schiötz ophthalmotonometer before the intravitreal injection and at 1, 4, 8, and 12 weeks after injection. There was no significant difference in intraocular pressure between any groups (p\>0.05) or between any time points (p\>0.05).](mv-v20-629-f4){#f4}

![Electroretinography b-wave amplitudes for each group at different time points. Electroretinography was performed before intravitreal injection and at 4 and 12 weeks after injection. No significant difference was observed in b-wave amplitudes between any groups (p\>0.05) or between any time points (p\>0.05).](mv-v20-629-f5){#f5}

![Light microscopic examination of the rabbit retina at 3 months (stain, hematoxylin-eosin; magnification, ×400). **A**: Intravitreal injection of physiologic salt solution. **B**: Intravitreal injection of 4 mg triamcinolone acetonide (TA). **C**: Intravitreal injection of 8 mg TA. The three figures show clear retina layers and normal structure. Bar = 20 μm.](mv-v20-629-f6){#f6}

![Transmission electron microscopic examination of rabbit retina at 3 months. Ultrastructure of rabbit retina at 3 months after intravitreal injection of PSS (**A**, **B**, **C**, **D**), 4 mg triamcinolone acetonide (TA; **E**, **F**) and 8 mg TA (**G**, **H**). No histological changes were verified in all retinas from the groups. The cells of outer nuclear layer (**A**, **E**), inner nuclear layer (**B**, **F**), inner segment of photoreceptor (**C**, **G**), and outer segment of photoreceptor (**D**, **H**) were all normal. Bar=2.5 μm in **B**, **D** and **E**, 2.0 μm in **A**, **C**, **F**, **G**, and **H**.](mv-v20-629-f7){#f7}

Discussion
==========

Due to the inner and outer blood--retinal barriers, systemic drugs barely reach the vitreous. To increase local ophthalmic drugs and limit the risk of systemic adverse effects, intravitreal injection has been applied in clinical treatment \[[@r28]\]. In 1980, Tano et al. \[[@r29]\] reported intravitreal injection of TA for therapy of proliferative vitreoretinopathy for the first time, and thereafter the use of intravitreal TA has gradually increased in ophthalmic diseases.

However, there are few reports about the pharmacokinetics of intravitreal injection of TA. Chin et al. \[[@r13]\] reported that the half-lives of intravitreal 0.3 mg TA for rabbits were 1.57 days in the vitrectomized group and 2.89 days in the nonvitrectomized group. Kim et al. \[[@r14]\] demonstrated that the half-lives of intravitreal 4 mg Kenalog and TA preservative-free were 23 days and 24 days, respectively. From these studies, we can infer that drug clearance may be enhanced by vitrectomy, and different intravitreal doses of TA may cause different elimination half-lives. Ophthalmologists always intravitreally injected 4 mg TA for patients, and most did not undergo vitrectomy. Therefore, this study selected 4 mg as the small dose of TA for the nonvitrectomized rabbits. We analyzed the pharmacokinetics of intravitreal commercial TA of 4 mg and 8 mg because the report showed there was no difference in vitreous levels of TA compared to TA preservative-free \[[@r14]\]. Additionally, removing preservatives could increase the risk of contamination.

This study showed that the half-life of intravitreal injection of 8 mg TA in rabbits was longer than that of 4 mg TA, and the initiate concentration of intravitreal 8 mg TA was also significant higher than that of 4 mg TA. The longer vitreous half-life of higher dose of intravitreal drug might attribute to "saturation" of elimination mechanisms \[[@r30]\]. Thus, we could infer that the higher initial dose of TA could cause a longer half-life. Thus, the higher dose of TA in the vitreous could lead to longer drug exposure for treating chronic eye disorders. Clinically, a longer duration of a higher dose of TA may be of benefit for treating chronic eye diseases. In the study, the half-life of intravitreal 4 mg TA was 24 days, which was similar to the results of Kim et al. \[[@r14]\] that the half-life of intravitreal 4 mg Kenalog was 23 days. Taking account of the differences in anatomy and physiology between humans and rabbits, caution should be exercised when analyzing pharmacokinetic study using rabbit models.

Some researchers believed that the retinal toxicity associated with TA might be due to its preservative, benzyl alcohol \[[@r20],[@r22],[@r25],[@r31]\]. Chang et al. \[[@r31]\] considered that the preserved commercial TA suspensions damaged human retinal pigment epithelial cells, but the preservative-free solutions did not. Macky et al. \[[@r32]\] believed benzyl alcohol produced severe ERG and structural damage to the retina when injected intravitreally. However, Dierks \[[@r19]\], Li \[[@r23]\], and Ruiz-Moreno \[[@r26]\] drew a complete opposite conclusion that the benzyl alcohol of 0.1 ml commercial TA did not show any toxicity to the retina. In this research, we used commercial TA, and the results demonstrated that IOP, ERG b-wave, light, and electron microscopy did not show significant differences in any groups, which were consistent with other studies \[[@r14],[@r19],[@r24],[@r26],[@r27]\]. In clinical analyses, intravitreal TA is associated with common side effects such as raised IOP and cataract, especially IOP elevation \[[@r33]-[@r35]\]. However, in most previous human reports regarding use of high-dose TA for intravitreal injections, no significant differences in IOP elevation were found between low-dose and high-dose intravitreal TA treatment \[[@r36]-[@r38]\]. Wei et al. \[[@r39]\] suggested that a higher dose of TA could be used if there was no IOP elevation with the initial lower dose of TA injection. Notwithstanding the histopathologic findings, ERG and IOP suggested no difference in the toxicity of 8mg TA, many other factors, especially the IOP elevation, should also be considered for the safety of intravitral 8mg TA in human eyes.

In conclusion, intravitreal injection of 4 mg and 8 mg TA was safe for the rabbits, and the higher TA dose had a longer effect. Consequently, these rabbit data provide a reasonable reference to the clinical application of intravitreal injection of TA.
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